Fresenius Lost Chance To Appeal Antitrust Suit, 3rd Circ. Told

Drugmaker Par Pharmaceutical urged the Third Circuit to deny health care company Fresenius Kabi USA's petition for a panel to rehear its antitrust case alleging Par delayed Fresenius from marketing a...

Already a subscriber? Click here to view full article